SenesTech Inc (NASDAQ:SNES) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus price target of $2.50 for the company, according to Zacks. Zacks has also assigned SenesTech an industry rank of 76 out of 256 based on the ratings given to its competitors.
Separately, ValuEngine downgraded WideOpenWest from a “hold” rating to a “sell” rating in a research report on Friday, June 28th.
SenesTech (NASDAQ:SNES) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $0.02 million for the quarter. SenesTech had a negative return on equity of 186.65% and a negative net margin of 3,908.08%. Analysts predict that SenesTech will post -0.19 earnings per share for the current year.
A hedge fund recently raised its stake in SenesTech stock. Virtu Financial LLC grew its holdings in shares of SenesTech Inc (NASDAQ:SNES) by 87.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,447 shares of the company’s stock after buying an additional 26,322 shares during the period. Virtu Financial LLC owned 0.24% of SenesTech worth $69,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 7.73% of the company’s stock.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.